Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

BCS
Home/The Filing Wire/X4 Pharmaceuticals, Inc./ SCHEDULE 13G/A

Beneficial Ownership Report · SCHEDULE 13G/A

X4 Pharmaceuticals, Inc.

XFORNASDAQEQUITYCurrent

Beneficial Ownership Report

Filed Aug 14, 2026Accepted Aug 14, 2026, 8:34 AM EDTCIK 1501697Accession 0001172661-26-003487
View company →Permanent SEC source ↗
Share

Company context

X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare hematology diseases and significant unmet needs. Leveraging expertise in CXCR4, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is currently being marketed in the U.S. as XOLREMDI® in its first indication. The company is also evaluating additional uses of mavorixafor and is conducting a global, pivotal Phase 3 clinical trial (4WARD) in people with certain

Current securities

XFORNASDAQ · EQUITY · Current
Historical securities (2)
XFORWOTC · WARRANT · Historical · closed Apr 9, 2024XFOWWOTC · WARRANT · Historical · closed Dec 28, 2022

Recent company filings

  1. 144 filingOct 1, 2026
  2. Other EventsSep 9, 2026
  3. Other EventsSep 8, 2026
  4. 4 filingAug 13, 2026
  5. 4 filingAug 13, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.